Contents
October 2016
Vol 1, Issue 4
Vol 1, Issue 4
Focus
- Interfer’n with antibody responses
Type I interferon blocks the generation of neutralizing antibodies in response to chronic infection.
Research Articles
- Inhibition of HDAC8 and HDAC9 by microbial short-chain fatty acids breaks immune tolerance of the epidermis to TLR ligands
Microbial short-chain fatty acids inhibit HDAC activity and contribute to keratinocyte-triggered skin inflammation.
- Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation
Type I interferon–driven CD8+ T cells suppress neutralizing antibody production during chronic LCMV infection.
- Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Interferon-driven inflammation in chronic viral infection blocks generation of sustained B cell responses.
- Inflammatory monocytes hinder antiviral B cell responses
LCMV evades B cell responses by recruiting inflammatory monocytes to draining lymph nodes.
- Group B Streptococcus circumvents neutrophils and neutrophil extracellular traps during amniotic cavity invasion and preterm labor
Group B streptococci overcome neutrophils in placental membranes, inducing fetal injury and preterm labor.
- Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome
Clinical transplant outcomes reflect the balance between host-versus-graft and graft-versus-host reactivities.
About The Cover
ONLINE COVER Transplantation Balancing Act. Successful organ transplantation depends on both preventing immune cells from the transplant recipient from rejecting the graft and blocking immune cells from the graft from attacking the host. Zuber et al. demonstrate that a balance in this two-way alloreactivity affects clinical outcomes in human intestinal allograft recipients. [CREDIT: ERAXION/ISTOCKPHOTO.COM]
